Rosacea is a common inflammatory skin condition that affects more than 16 million people in the US.1


Rosacea is a chronic condition characterized by facial redness, flushing, and visible blood vessels. Papulopustular rosacea can result in redness, swelling, and/or pus-filled bumps.1 There may be several factors that contribute to the cause of rosacea, including genetics, environmental factors, an overactive immune system, and Demodex mites.2-4

magnifying glass eye

Demodex mites are highly prevalent in the skin of patients with rosacea and may contribute to the inflammatory response associated with the disease.5

Identifying the disease

Rosacea signs and symptoms often vary by individual and regularly fluctuate between periods of exacerbation, often referred to as a “flare up,” and remission.2,6 Common rosacea triggers include (but are not limited to)2,7,8

  • Alcohol or spicy foods
  • Emotional stress or physical exertion, like exercise
  • Extreme temperatures
  • Certain medications, cosmetics, or skincare products

There are no preventative or curative therapies for rosacea. Current management options include topical and oral antimicrobials,9 but the condition can be challenging to treat.

An investigational therapeutic is being studied for the treatment of papulopustular rosacea.

Learn about TP-04

1. Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res.2018.7 2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. Journal of the American Academy of Dermatology. 2002;46(4):584-587 3. McAleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144(6):663-671. 4. Chang YS and Huang YC. Role of Demodex mite infestation in rosacea: A systemic review and meta-analysis. J Am Acad Dermatol 2017; 77(3): 441-447. 5. Forton FMN. The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea? Dermatology and Therapy. 2020;10(6):1229-1253. 6. Rainer B, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermato-endocrinology 2017; 9(1): e1361574. 7. Aksoy B, Altaykan-Hapa A, Egemen D, et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010; 163:719. 8. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-341. 9. McGregor SP, Alinia H, Snyder A, Tuchayi SM, Fleischer A, Jr., Feldman SR. A Review of the Current Modalities for the Treatment of Papulopustular Rosacea. Dermatologic clinics. 2018;36(2):135-150

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.